Phase 3 study of BIVV003
Latest Information Update: 11 Aug 2022
At a glance
- Drugs ST 400 (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
Most Recent Events
- 11 Aug 2022 New trial record
- 04 Aug 2022 According to a Sangamo Therapeutics media release, trial enabling activities and manufacturing readiness are in progress.